Core Viewpoint - The chromatography market is experiencing significant growth driven by demand from downstream sectors such as biopharmaceuticals, food safety, environmental monitoring, and petrochemicals, with a notable increase in market size projected for the coming years [1][5][8]. Chromatography Industry Definition and Technology Classification - Chromatography, also known as layer chromatography, is a physical and chemical analysis method that separates different solutes based on their interactions with stationary and mobile phases [2]. Current Development Status of the Chromatography Industry - The global chromatography column market is expected to reach USD 3.169 billion in 2024, with North America accounting for 37.27% of the market share [5]. - In China, the chromatography industry is projected to grow to CNY 25.968 billion in 2024, with specific market sizes for chromatography columns, instruments, and media being CNY 2.053 billion, CNY 11.029 billion, and CNY 12.886 billion respectively [1][8]. Regional Demand Characteristics - In China, the demand for chromatography products is regionally concentrated, with East China accounting for 38.50% of the market in 2024, followed by Central South and Western regions [10]. Industry Chain of Chromatography - The chromatography industry operates upstream in the pharmaceutical industry chain, primarily sourcing chemical reagents and instrument components, which are widely available and competitively priced [12]. Development History of the Chromatography Industry - The development of chromatography technology in China began in the 1950s, with significant milestones including the first commercial gas chromatography instrument produced in 1963 [14]. Competitive Landscape of the Chromatography Industry - The domestic chromatography market is becoming increasingly competitive as local pharmaceutical companies seek to replace imported products with high-quality domestic alternatives due to cost control measures [17]. Development Trends in the Chromatography Industry - The demand for chromatography analysis is growing across various sectors, including biopharmaceuticals and food safety, leading to an expanding market size and a clear trend towards domestic production capabilities that can compete with international leaders [20].

Core Viewpoint - Jiangsu Hanbang Technology Co., Ltd. has successfully listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, with a closing price of 46.10 yuan, representing a 102.46% increase on the first day of trading [1] Company Overview - Hanbang Technology focuses on chromatography technology, integrating research and development, production, and sales, primarily serving the pharmaceutical and life sciences sectors with specialized separation and purification equipment, consumables, and technical solutions [1] - The company is controlled by Zhang Dabin, who holds 23.75% of the shares directly and has a total control of 28.94% post-IPO [1] IPO Details - The company issued 22,000,000 shares at a price of 22.77 yuan per share, raising a total of 500.94 million yuan, with a net amount of 430.67 million yuan after deducting issuance costs [4] - The total issuance costs amounted to 70.27 million yuan, with underwriting fees of 37.29 million yuan [6] Financial Performance - For the years 2022 to 2024, the company reported revenues of 481.79 million yuan, 619.01 million yuan, and 690.88 million yuan, respectively, with net profits of 38.56 million yuan, 51.50 million yuan, and 79.34 million yuan [6][7] - In the first quarter of 2025, the company achieved total revenue of 165.23 million yuan, a year-on-year increase of 19.88%, and a net profit of 11.10 million yuan, up 93.79% from the previous year [9][10] Project Funding Allocation - The raised funds will be allocated to three main projects: 1. Annual production of 1,000 units of liquid chromatography separation equipment (19.30 million yuan) 2. Construction of a chromatography separation equipment R&D center (27.11 million yuan) 3. Annual production of 2,000 units of laboratory chromatography separation and purification instruments (22.48 million yuan) [5]

Core Viewpoint - Jiangsu Hanbang Technology Co., Ltd. officially listed on the Sci-Tech Innovation Board with an initial price of 22.77 yuan per share, opening with a significant increase of 115%, resulting in a market value exceeding 4.3 billion yuan [1] Company Overview - Hanbang Technology has received considerable attention and recognition from local government officials, indicating its successful development and contributions to the industry [2] - The company has evolved from a small startup to a leading player in the chromatography field, reflecting the growth of China's chromatography industry [6][12] Technological Development - Chromatography technology, originating in 1906, has evolved to play a crucial role in various fields, including sports doping detection and food safety analysis, and is essential in biopharmaceuticals [4] - Hanbang Technology focuses on core chromatography technologies, including chromatography column technology, system integration, and application, driving innovation in the field [14][15] Talent Acquisition and Corporate Culture - The company emphasizes the importance of talent, establishing a strong team of professionals, including 7 PhDs and over 40 Masters, to foster innovation [9][11] - Hanbang Technology promotes a supportive work environment that values employee growth and satisfaction, contributing to a culture of innovation [11] Innovation and Market Position - Hanbang Technology aims to become the leading brand in the international chromatography industry, leveraging its innovative capabilities to enhance product offerings [12][20] - The company has achieved significant milestones in technology, including breakthroughs in large-scale production processes for biopharmaceuticals, contributing to the "domestic substitution" trend [15] Global Expansion - Hanbang Technology is actively pursuing international markets, establishing a wholly-owned subsidiary in Singapore to enhance its global presence and brand influence [23] - The company has successfully expanded its market reach across Europe and Asia, gaining recognition and building a strong reputation in the global chromatography sector [23]

Core Viewpoint - Jiangsu Hanbang Technology Co., Ltd. (Hanbang Technology) is set to launch its IPO on the Shanghai Stock Exchange's Sci-Tech Innovation Board, with a reduced fundraising target of approximately 430 million yuan, down from earlier projections of 980 million yuan and 598 million yuan [3][4][5]. Fundraising and Financials - The IPO price is set at 22.77 yuan per share, with a total issuance of 22 million shares, aiming to raise around 500 million yuan [3]. - The net fundraising amount has decreased by approximately 56%, equating to a reduction of 550 million yuan compared to earlier estimates [5]. - The company plans to allocate the raised funds primarily for production projects, including the annual production of 1,000 liquid chromatography separation equipment and the development of chromatography separation equipment [4][5]. Company Overview - Hanbang Technology, established in October 1998, focuses on chromatography technology, providing separation and purification equipment, consumables, and technical solutions primarily for the pharmaceutical and life sciences sectors [6]. - The company has a registered capital of 66 million yuan, with major shareholders including Zhang Dabin, WuXi AppTec, QK Venture Capital, and Sequoia [6]. Performance Metrics - Revenue projections for Hanbang Technology are approximately 482 million yuan for 2022, 619 million yuan for 2023, and 691 million yuan for 2024, with net profits of around 38.56 million yuan, 51.50 million yuan, and 79.34 million yuan respectively [7]. - The company has shown a compound annual growth rate (CAGR) of 38.99% in main business revenue from 2021 to 2023, but this rate is expected to slow to 19.78% from 2022 to 2024 [9]. - The total assets as of December 31, 2024, are projected to be approximately 1.32 billion yuan, with a debt-to-asset ratio of 44.17% [8].

Core Viewpoint - Hanbang Technology (688755.SH) is set to be listed on the Sci-Tech Innovation Board, focusing on chromatography technology to provide separation and purification equipment and solutions for the pharmaceutical and life sciences sectors [1][2] Company Overview - Hanbang Technology is a high-tech enterprise integrating R&D, production, and sales, primarily serving the pharmaceutical and life sciences industries [1] - The company has established itself as a leading player in the domestic chromatography purification equipment market, with a market share of approximately 12.7% in small molecule liquid chromatography equipment, ranking first among domestic manufacturers [6] - Hanbang's product lines include small molecule and large molecule drug separation and purification equipment, catering to both industrial production and laboratory research [6] Financial Information - The company's initial public offering (IPO) price is set at 22.77 CNY per share, with an institutional offering price of 23.00 CNY per share, resulting in a market capitalization of 15.03 billion CNY [5] - The projected use of raised funds includes investments in various production projects, with amounts allocated as follows: 1.93 billion CNY for annual production of 1,000 liquid chromatography separation equipment, 1.81 billion CNY for chromatography equipment R&D center, and 2.25 billion CNY for annual production of 2,000 laboratory chromatography purification instruments [5] Market Position and Competitors - Hanbang Technology has established strong partnerships with well-known pharmaceutical companies such as Hengrui Medicine, Zhengda Tianqing, and others, and its products are exported to multiple countries including Germany, the UK, India, and South Korea [6] - The company has undergone multiple rounds of financing, with notable investors including WuXi AppTec, Junlian Capital, and Sequoia Capital [6] Risks and Challenges - The company has reported high ending inventory amounts and potential impairment risks, with inventory values of 508 million CNY, 431 million CNY, and 387 million CNY from 2022 to 2024 [7] - Accounts receivable values are also significant, with amounts of 131 million CNY, 119 million CNY, and 130 million CNY for the same period, indicating a high proportion of overdue accounts [7]

Core Viewpoint - Hanbang Technology (688755.SH) has initiated its subscription with an issue price of 22.77 yuan per share and a price-to-earnings ratio of 26.35 times, focusing on chromatography technology for pharmaceutical and life sciences sectors [1] Company Overview - Hanbang Technology is a high-tech enterprise that integrates research and development, production, and sales, primarily providing separation and purification equipment, consumables, application technology services, and related technical solutions for the pharmaceutical and life sciences industries [1] - The company's products are widely used in the research and production of antibodies, recombinant proteins, vaccines, insulin, peptides, contrast agents, antibiotics, and natural products [1] Product Segmentation - The main products are categorized into small molecule drug separation and purification equipment and large molecule drug separation and purification equipment, applicable in various industrial production and laboratory research scenarios [1] - The small molecule liquid chromatography equipment is divided into laboratory instruments and production-grade equipment, with Hanbang Technology ranking second in the production-grade liquid chromatography separation equipment market in China, holding approximately 12.7% market share [4] Financial Performance - The company reported revenues of approximately 321 million yuan, 482 million yuan, and 619 million yuan for the years 2021, 2022, and 2023, respectively [6] - Net profits for the same years were approximately 4.86 million yuan, 38.56 million yuan, and 51.50 million yuan [6] Market Position - According to data from Sullivan, the total market size for liquid chromatography equipment in China exceeded 2.7 billion yuan in 2023, with Agilent holding the largest market share at 23.2% [4] - Hanbang Technology has sold its products to over 2,000 customers domestically and internationally, including well-known pharmaceutical companies such as Sitaly, Ganli Pharmaceutical, and China National Pharmaceutical Group [3] Investment Projects - The company plans to use the raised funds for projects including the annual production of 1,000 units of liquid chromatography series separation equipment, the establishment of a chromatography separation equipment R&D center, and the annual production of 2,000 laboratory chromatography separation and purification instruments [9]

Core Viewpoint - The company, Jiangsu Hanbang Technology Co., Ltd., focuses on chromatography technology, aiming to become the leading brand in the international chromatography industry while providing high-quality separation and purification equipment for the pharmaceutical and life sciences sectors [4][5][7]. Business Overview - The company specializes in chromatography separation and purification products, offering a comprehensive product matrix that includes small and large molecule drug separation and purification equipment [5]. - The main product lines include small molecule liquid chromatography systems and large molecule chromatography systems, catering to both laboratory research and industrial production [5]. R&D Model - The company adopts an independent R&D model with dedicated departments for instrument development, application technology, and new materials [6]. - R&D strategies are guided by customer needs and industry trends, leading to the development of new products and continuous improvement of existing ones [6]. Core Technology - The company has developed unique core technologies in chromatography, including preparation chromatography column technology and integrated chromatography system technology [7]. - It has undertaken multiple national and provincial research projects, enhancing its technological capabilities [7]. Financial Performance - The company's revenue for 2022, 2023, and 2024 was approximately 481.79 million, 619.01 million, and 690.88 million yuan, respectively, with over 99% of revenue coming from its main business [11]. - Gross profit for the same years was approximately 189.24 million, 245.08 million, and 293.57 million yuan, showing a consistent growth trend [11]. Product Profitability - The gross profit margin for small molecule drug separation and purification equipment was 43.87%, 42.13%, and 46.90% from 2022 to 2024, while for large molecule equipment, it was 31.79%, 34.72%, and 31.55% [12]. Future Development Plans - The company plans to continue focusing on chromatography products, enhancing R&D and innovation, and expanding its product range in the biopharmaceutical chromatography purification field [13]. - Specific measures include strengthening talent development, enhancing marketing and service capabilities, and diversifying financing [13]. Competitive Advantages - The company possesses several competitive advantages, including technological innovation, comprehensive solution services, brand leadership, rapid response, and strong customer resources [14][19]. Industry Trends - The pharmaceutical equipment industry is experiencing rapid growth driven by the Chinese pharmaceutical market, with increasing demand for both small and large molecule chromatography systems [20][21]. - The industry is also seeing a shift towards high-end products and smart manufacturing, supported by national policies [21]. Market Position - The company ranks second in the production-level small molecule liquid chromatography equipment market in China, with a market share of approximately 12.7% [22]. - In the production-level small molecule liquid chromatography system market, the company holds a leading position with a market share of 39.2% [22]. Fundraising Projects - The company plans to invest in projects including the annual production of 1,000 liquid chromatography series separation equipment and the establishment of a chromatography separation equipment R&D center [24][25][26].